The ability of PC1 to antagonize Aβ toxicity on the one hand, and LTP impairment in the APP Tg2576 mouse model of AD on the other, suggests that injury-induced PROK2 expression is deleterious and that blocking of the prokineticin system may be therapeutic. This evidence concerns the gene PROK2 and Alzheimer disease.